Peptide name : [R4A, R18A]cGm

Source/Organism : Synthetic Analogue of Gomesin

Linear/Cyclic : Cyclic

Chirality : L

Peptide length: 18

C-terminal modification: Cyclic

N-terminal modification : Cyclized

Non-natural peptide information:

Assay type : Resazurin dye assay

Assay time : 24-h

Activity : CC50 > 64 μM

Cell line : HeLa

Cancer type : Cervical Cancer

Other activity : Antimicrobial

Amino acid composition bar chart :

Molecular mass : 2051.4428 Dalton

Aliphatic index : 0.488

Instability index : 4.2389

Hydrophobicity (GRAVY) : -0.188

Isoelectric point : 9.2497

Charge (pH 7) : 3.7175

Aromaticity : 11.11

Molar extinction coefficient (cysteine, cystine): (4, 2)

Hydrophobic/hydrophilic ratio : 1.25

hydrophobic moment : 0.6457

Missing amino acid : D,E,F,H,I,M,N,P,S,W

Most occurring amino acid : C

Most occurring amino acid frequency : 4

Least occurring amino acid : L

Least occurring amino acid frequency : 1

Secondary structure fraction (Helix, Turn, Sheet): (22., 11., 27.)

SMILES Notation: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)CN)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)O)[C@@H](C)O)C(C)C

1 : Liu X, et al. Unlocking the Potential of the Antimicrobial Peptide Gomesin: From Discovery and Structure-Activity Relationships to Therapeutic Applications. Int J Mol Sci. 2023; 24:(unknown pages). doi: 10.3390/ijms24065893

Paper title : Unlocking the Potential of the Antimicrobial Peptide Gomesin: From Discovery and Structure-Activity Relationships to Therapeutic Applications.

Doi : https://doi.org/10.3390/ijms24065893

Abstract : Gomesin is a cationic antimicrobial peptide which is isolated from the haemocytes of the Brazilian tarantula Acanthoscurria gomesiana and can be produced chemically by Fmoc solid-phase peptide synthesis. Gomesin exhibits a range of biological activities, as demonstrated by its toxicity against therapeutically relevant pathogens such as Gram-positive or Gram-negative bacteria, fungi, cancer cells, and parasites. In recent years, a cyclic version of gomesin has been used for drug design and development as it is more stable than native gomesin in human serum and can penetrate and enter cancer cells. It can therefore interact with intracellular targets and has the potential to be developed as a drug lead for to treat cancer, infectious diseases, and other human diseases. This review provides a perspective on the discovery, structure-activity relationships, mechanism of action, biological activity, and potential clinical applications of gomesin.